[go: up one dir, main page]

BE2014C068I2 - - Google Patents

Info

Publication number
BE2014C068I2
BE2014C068I2 BE2014C068C BE2014C068C BE2014C068I2 BE 2014C068 I2 BE2014C068 I2 BE 2014C068I2 BE 2014C068 C BE2014C068 C BE 2014C068C BE 2014C068 C BE2014C068 C BE 2014C068C BE 2014C068 I2 BE2014C068 I2 BE 2014C068I2
Authority
BE
Belgium
Prior art keywords
present
immunoglobulin
humanized
human
humanized immunoglobulin
Prior art date
Application number
BE2014C068C
Other languages
French (fr)
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24814673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C068(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BE2014C068I2 publication Critical patent/BE2014C068I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to humanized immunoglobulins having binding specificity for ±4²7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In one embodiment, the humanized immunoglobulin can compete with murine Act-1 for binding to human ±4²7 integrin. In a preferred embodiment, the antigen binding region of the humanized immunoglobulin comprises each of the complementarity determining regions of the light and heavy chains of the murine Act-1 antibody. The present invention further relates to a humanized immunoglobulin light chain or heavy chain, isolated nucleic acids comprising a sequence which encodes a humanized immunoglobulin or immunoglobulin chain of the present invention (e.g., a single chain antibody), constructs comprising a nucleic acid of the present invention, and host cells comprising a nucleic acid of the present invention useful in a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in diagnostic and therapeutic applications in humans, for example to control lymphocyte infiltration (including recruitment and/or accumulation) to mucosal tissue.
BE2014C068C 1996-08-15 2014-11-12 BE2014C068I2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/700,737 US7147851B1 (en) 1996-08-15 1996-08-15 Humanized immunoglobulin reactive with α4β7 integrin

Publications (1)

Publication Number Publication Date
BE2014C068I2 true BE2014C068I2 (en) 2017-09-22

Family

ID=24814673

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C068C BE2014C068I2 (en) 1996-08-15 2014-11-12

Country Status (19)

Country Link
US (3) US7147851B1 (en)
EP (2) EP0918797B2 (en)
JP (3) JP4171071B2 (en)
CN (1) CN100406562C (en)
AT (1) ATE321788T1 (en)
AU (1) AU730326C (en)
BE (1) BE2014C068I2 (en)
BR (1) BRPI9711079B1 (en)
CA (1) CA2263106C (en)
DE (1) DE69735596T3 (en)
DK (1) DK0918797T4 (en)
ES (1) ES2262186T5 (en)
IL (3) IL128052A0 (en)
LT (1) LTC0918797I2 (en)
LU (1) LU92596I2 (en)
NZ (1) NZ334226A (en)
PT (1) PT918797E (en)
SI (1) SI0918797T2 (en)
WO (1) WO1998006248A2 (en)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7090845B2 (en) * 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
AU2011226857B2 (en) * 1998-05-13 2013-09-19 Genentech, Inc. Diagnosis and treatment of hepatic disorders
WO2000030681A1 (en) * 1998-11-25 2000-06-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
GEP20063844B (en) * 1999-04-22 2006-06-12 Biogen Idec Inc Using antagonist of integrin alpha-4 subunit for treatment of fibrosis
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
AU2006220426B2 (en) * 2000-04-14 2008-10-30 Genentech Inc. Method of administering an antibody
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
AU2002366303B2 (en) * 2001-12-17 2007-09-20 University College Cardiff Consultants Limited Enzymatic cleavable reagents for specific delivery to disease sites
DK1472275T3 (en) 2002-02-05 2009-04-14 Genentech Inc protein purification
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
SG165158A1 (en) 2002-05-02 2010-10-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AU2004204494B2 (en) * 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006516639A (en) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド Active immunization to generate antibodies against soluble A-beta
JP4599355B2 (en) 2003-07-28 2010-12-15 ジェネンテック， インコーポレイテッド Reduction of protein A leaching during protein A affinity chromatography
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
EP1631311A4 (en) 2003-12-10 2007-04-11 Millennium Pharm Inc Humanized anti-ccr2 antibodies and methods of use
PA8621301A1 (en) 2004-01-09 2006-09-22 Pfizer ANTIBODIES AGAINST MAdCAM
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
PT2990422T (en) 2004-09-03 2018-10-18 Genentech Inc Humanized anti-beta7 antagonists and uses therefor
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2007007160A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat fever
WO2007007151A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Use of anti-mad-cam antibody for the treatment of emphysema
WO2007061679A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
FR2902799B1 (en) 2006-06-27 2012-10-26 Millipore Corp METHOD AND UNIT FOR PREPARING A SAMPLE FOR THE MICROBIOLOGICAL ANALYSIS OF A LIQUID
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
MX2009007632A (en) 2007-01-22 2009-07-24 Genentech Inc Polyelectrolyte precipitation and purification of proteins.
ES2707551T3 (en) * 2007-03-02 2019-04-04 Amgen Inc Methods and compositions for treating tumor diseases
EP2125892A2 (en) * 2007-03-20 2009-12-02 Millennium Pharmaceuticals, Inc. Nucleic acids encoding humanized immunoglobulin that binds a4b7 integrin
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN101849001B (en) 2007-06-25 2014-07-16 艾斯巴技术-诺华有限责任公司 Methods of modifying antibodies, and modified antibodies with improved functional properties
KR20190140090A (en) 2007-07-09 2019-12-18 제넨테크, 인크. Prevention of disulfide bond reduction during recombinant production of polypeptides
SI2182983T1 (en) * 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
JP5237382B2 (en) 2007-10-30 2013-07-17 ジェネンテック， インコーポレイテッド Purification of antibodies by cation exchange chromatography.
WO2009088065A1 (en) * 2008-01-11 2009-07-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute HUMANIZED ANTI-HUMAN α9-INTEGRIN ANTIBODY
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
ES2978373T3 (en) 2008-08-14 2024-09-11 Genentech Inc Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
BRPI0918978A2 (en) 2008-09-10 2015-12-01 Genentech Inc compositions and methods the prevention of oxidative degradation of proteins
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
CN105037535A (en) 2008-12-16 2015-11-11 Emd密理博公司 Stirred tank reactor and method
SG173812A1 (en) 2009-02-27 2011-09-29 Genentech Inc Methods and compositions for protein labelling
AU2016208453B2 (en) * 2009-03-20 2018-02-22 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
AU2013205341B2 (en) * 2009-03-20 2016-05-05 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
PE20120497A1 (en) * 2009-03-20 2012-05-14 Amgen Inc ANTIBODY SPECIFIC ANTAGONIST FOR ALPHA-4-BETA-7 HETERODIMER
CA2939492C (en) 2009-05-13 2019-03-19 Genzyme Corporation Anti-human cd52 immunoglobulins
JP5930542B2 (en) 2009-08-11 2016-06-08 ジェネンテック， インコーポレイテッド Protein production in glutamine-free cell culture media
EP3736338A1 (en) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Enhanced protein purification through a modified protein a elution
CA2773522C (en) 2009-10-26 2023-04-18 Chugai Seiyaku Kabushiki Kaisha Method for the production of a glycosylated immunoglobulin
HRP20190751T1 (en) 2010-03-22 2019-06-14 F. Hoffmann - La Roche Ag PREPARATIONS AND PROCEDURES USEFUL FOR STABILIZATION OF PROTEIN CONTAINING FORMULATIONS
EP2566510A1 (en) 2010-05-03 2013-03-13 F. Hoffmann-La Roche AG Compositions and methods useful for reducing the viscosity of protein-containing formulations
CN102892791B (en) 2010-05-17 2017-05-17 Emd密理博公司 Stimulus responsive polymers for the purification of biomolecules
CA2800728C (en) 2010-05-28 2020-10-27 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
MY161390A (en) 2010-06-24 2017-04-14 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
CN103154032A (en) 2010-08-13 2013-06-12 弗·哈夫曼-拉罗切有限公司 Antibodies to IL-1beta and IL-18, for treatment of disease
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
SMT201700515T1 (en) 2011-05-02 2018-01-11 Millennium Pharm Inc Formulation for anti- 4 7 antibody
UA116189C2 (en) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. COMPOSITION OF ANTI-α4β7 ANTIBODY
WO2012178102A2 (en) 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
MX360453B (en) 2011-12-22 2018-11-01 Genentech Inc Ion exchange membrane chromatography.
WO2013106589A1 (en) * 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EA034583B1 (en) * 2012-01-12 2020-02-21 Милленниум Фармасьютикалз, Инк. USES OF ANTI-α4β7 ANTIBODY
EP2831261B1 (en) 2012-03-27 2017-10-18 F. Hoffmann-La Roche AG Method for producing recombinant proteins with low levels of DHNA (1,4-dihydroxy-2-naphthoate)
CN103374073A (en) * 2012-04-26 2013-10-30 中国科学院上海生命科学研究院 Humanized monoclonal antibody that recognizes the activated form of integrin α4β7
SG11201407512VA (en) 2012-05-18 2014-12-30 Genentech Inc High-concentration monoclonal antibody formulations
CN104994885B (en) 2012-12-19 2017-09-29 基因泰克公司 Method and composition for radiohalogen protein labeling
AR095199A1 (en) 2013-03-15 2015-09-30 Genzyme Corp ANTI-CD52 ANTIBODIES
EP3777535A1 (en) 2014-07-09 2021-02-17 F. Hoffmann-La Roche AG Ph adjustment to improve thaw recovery of cell banks
EP3204424B1 (en) 2014-10-06 2023-11-29 ChemoCentryx, Inc. Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease
US20170327584A1 (en) 2014-11-26 2017-11-16 Millennium Pharmaceuticals, Inc. Vedolizumab for the Treatment of Fistulizing Crohn's Disease
JP6904905B2 (en) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Predicting the outcome of treatment with anti-α4β7 integrin antibody
MA41636A (en) 2015-03-06 2018-01-09 Millennium Pharm Inc METHOD OF TREATMENT OF PRIMITIVE SCLEROSANT CHOLANGITIS
CN107922938B (en) * 2015-08-11 2021-09-17 国立大学法人大阪大学 Antibodies
JP6951825B2 (en) 2015-09-04 2021-10-20 ザ スクリプス リサーチ インスティテュート Insulin immunoglobulin fusion protein
US20190008935A1 (en) 2015-12-31 2019-01-10 The Regents Of The University Of Colorado, A Bodo Corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications
CN117298268A (en) 2016-03-14 2023-12-29 千禧制药公司 Methods of treating or preventing graft versus host disease
MA44408A (en) * 2016-03-14 2019-01-23 Millennium Pharm Inc METHOD OF TREATING GRAFT-VERSUS HOST REACTION (GVD)
JP7069032B2 (en) 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド Treatment of gastrointestinal immune-related adverse events in cancer immunotherapy
TW201735949A (en) 2016-03-24 2017-10-16 千禧製藥公司 Methods of treating gastrointestinal immune-related adverse events in anti-CTLA4 anti-PD-1 combination treatments
US10941406B2 (en) 2016-03-29 2021-03-09 Geltor, Inc. Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
JP7162533B2 (en) 2016-05-04 2022-10-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド Triple therapy for the treatment of inflammatory bowel disease
WO2017214376A1 (en) * 2016-06-10 2017-12-14 Elwha Llc Compositions and methods including b lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin and cytolytic function
WO2017218434A1 (en) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Method of treating inflammatory bowel disease
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
JP7553241B2 (en) 2016-12-22 2024-09-18 ジェネンテック， インコーポレイテッド Methods and formulations for reducing reconstitution time of lyophilized polypeptides - Patents.com
BR112019022268A2 (en) 2017-04-28 2020-05-19 Millennium Pharm Inc method for the treatment of pediatric disorders
CA3069914A1 (en) 2017-07-14 2019-01-17 Pfizer Inc. Antibodies to madcam
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
HRP20240584T1 (en) 2018-07-03 2024-07-19 Bristol-Myers Squibb Company Methods of producing recombinant proteins
EP3864127A1 (en) 2018-10-10 2021-08-18 Boehringer Ingelheim International GmbH Method for membrane gas transfer in high density bioreactor culture
AU2019387482A1 (en) * 2018-11-30 2021-06-17 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
CA3133652A1 (en) 2019-04-01 2020-10-08 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
TW202104254A (en) 2019-04-12 2021-02-01 美商格爾托公司 Recombinant elastin and production thereof
JP2022529929A (en) * 2019-04-17 2022-06-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド Combination therapy of α4β7 inhibitor and IL-23 inhibitor
US20220267448A1 (en) * 2019-06-10 2022-08-25 Takeda Pharmaceutical Company Limited Cell culture methods and compositions for antibody production
AR119268A1 (en) * 2019-06-10 2021-12-09 Millennium Pharm Inc METHODS OF PURIFICATION OF ANTIBODIES AND THEIR COMPOSITIONS
KR20220039777A (en) 2019-08-01 2022-03-29 브리스톨-마이어스 스큅 컴퍼니 Methods for improving protein productivity in fed-batch cell culture
US20230357815A1 (en) 2020-09-22 2023-11-09 Bristol-Myers Squibb Company Methods for increasing productivity of therapeutic proteins
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
WO2023245097A2 (en) 2022-06-16 2023-12-21 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
US20250195677A1 (en) 2023-12-19 2025-06-19 Cephalon Llc Uses for attenuated il-2 immunoconjugates
CN117777292B (en) * 2023-12-28 2024-10-18 天津大学 Anti-integrin alpha4β7Nanobody and use thereof
WO2025149974A1 (en) 2024-01-11 2025-07-17 Takeda Pharmaceutical Company Limited Combination therapy with an anti-alpha4beta7 antibody

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3220049A1 (en) 1982-05-27 1983-12-01 Universal Maschinenfabrik Dr. Rudolf Schieber GmbH & Co KG, 7081 Westhausen KNITTING AND SHOULDER LOCK COMBINATION FOR V-BED FLAT KNITTING MACHINES WITH SLIDING NEEDLES
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE3852236T2 (en) 1987-08-11 1995-04-06 Univ Leland Stanford Junior Procedure for controlling leukocyte extravasation.
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
JP3095168B2 (en) 1988-02-05 2000-10-03 エル． モリソン，シェリー Antibodies with domain-denaturing constants
EP0462111A4 (en) 1988-12-23 1992-07-08 The Board Of Trustees Of The Leland Stanford Junior University Homing sequences and their uses
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IL113261A (en) 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992015683A1 (en) 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
US5665595A (en) * 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
ATE151642T1 (en) 1992-02-12 1997-05-15 Biogen Inc TREATMENT FOR INFLAMMATORY DISEASE OF THE INTESTINAL
AU5732694A (en) 1992-12-01 1994-06-22 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
WO1994013312A1 (en) 1992-12-15 1994-06-23 The Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
HK1008731A1 (en) 1993-02-09 1999-05-14 Biogen Idec Ma Inc. Antibody for the treatment of insulin dependent diabetes
JPH06303990A (en) 1993-04-24 1994-11-01 Kanebo Ltd Monoclonal antibody, hybridoma capable of producing the same and production of the same antibody
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
KR100367948B1 (en) 1994-01-25 2003-07-12 엘란 파마슈티칼스, 인크. Humanized Antibody Against Leukocyte Adhesion Molecule VLA-4
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin

Also Published As

Publication number Publication date
JP5166483B2 (en) 2013-03-21
JP4578536B2 (en) 2010-11-10
JP2001507210A (en) 2001-06-05
PT918797E (en) 2006-08-31
HK1021822A1 (en) 2000-07-07
ES2262186T3 (en) 2006-11-16
US7147851B1 (en) 2006-12-12
JP2008281562A (en) 2008-11-20
CA2263106A1 (en) 1998-02-19
BRPI9711079B8 (en) 2021-05-25
US7402410B2 (en) 2008-07-22
US20090011464A1 (en) 2009-01-08
EP0918797B2 (en) 2015-09-23
DK0918797T4 (en) 2016-01-11
EP0918797A2 (en) 1999-06-02
IL128052A (en) 2006-08-20
AU730326B2 (en) 2001-03-01
DE69735596T2 (en) 2006-12-21
EP0918797B1 (en) 2006-03-29
JP4171071B2 (en) 2008-10-22
DE69735596T3 (en) 2016-02-25
BR9711079A (en) 2000-06-06
WO1998006248A2 (en) 1998-02-19
WO1998006248A3 (en) 1998-05-07
DK0918797T3 (en) 2006-07-31
IL175570A0 (en) 2006-09-05
SI0918797T1 (en) 2006-10-31
US20060292140A1 (en) 2006-12-28
CN100406562C (en) 2008-07-30
ES2262186T5 (en) 2015-12-11
ATE321788T1 (en) 2006-04-15
LTC0918797I2 (en) 2017-05-10
AU3972897A (en) 1998-03-06
LU92596I2 (en) 2015-01-12
CN1227607A (en) 1999-09-01
JP2010246548A (en) 2010-11-04
IL128052A0 (en) 1999-11-30
AU730326C (en) 2005-06-16
DE69735596D1 (en) 2006-05-18
EP1710314A1 (en) 2006-10-11
NZ334226A (en) 2000-10-27
BRPI9711079B1 (en) 2017-06-20
SI0918797T2 (en) 2016-01-29
CA2263106C (en) 2010-08-03

Similar Documents

Publication Publication Date Title
BE2014C068I2 (en)
PT699755E (en) METHOD FOR OBTAINING MODIFIED IMMUNOGLOBULINS WITH REDUCED IMMUNOGENICITY OF VARIABLE DOMAINS OF MURIDEO ANTIBODIES COMPOSITIONS THAT CONTAIN THEM
CY1107708T1 (en) HUMAN MONOCLONAL ANTIBODIES TO EPITERNAL GROWTH FACTOR RECEPTOR
BR9507594B1 (en) humanized scfv monoclonal antibody, recombinant nucleic acid molecule and recombinant protein.
WO1999037681A3 (en) Method for producing antibody fragments
ATE504601T1 (en) ANTI-CD3 ANTIBODIES FOR USE TO INDUCE IMMUNOSUPRESSION
EP1362868A3 (en) Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
DE69000338D1 (en) EXPRESSION SYSTEM FOR THE PRODUCTION OF CHIMERIC MONOCLONAL ANTIBODIES.
WO1998033919A3 (en) Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use
GR3020610T3 (en) Monoclonal antibodies against tumor associated antigen, their preparation and use
CA2068222A1 (en) Monoclonal antibodies
CA2185112A1 (en) Humanized monoclonal antibodies against human interleukin-4
WO1998012334A3 (en) Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
RU94045907A (en) Human hiv-antibodies or their fragments, expression casettes, host-cells, pharmaceutical composition, method of protection